Skip to Main Content

Advertisement

Skip Nav Destination
Newest Articles
Article
Marie Ménard et al.
This study describes a Mycn-nGEMM for neuroblastoma. Murine and human neuroblastomas showed profound immunosuppression mediated by PD-L1–expressing, TAMs. Anti–PD-L1 immunotherapy depleted TAMs and inhibited tumor growth, demonstrating the potential for myeloid-targeted immunotherapies to overcome the immuno-inhibitory barriers.
Article
Kun Yang et al.
NGLY1 deficiency is an early-onset neurodegenerative disorder with no effective therapy. Here, we describe an inducible Ngly1 knockout mouse model, iNgly1−/−, that reveals pronounced loss of Purkinje cells in the cerebellum without neuroinflammation. Sting1 knockout or STING inhibitor VS-X4 significantly rescues iNgly1−/− disease in mice.
Article
Quin T. Waterbury et al.
During obesity, the bone marrow is dysregulated to overproduce myeloid cells that drive systemic inflammation. Neutrophil migration is a key mediator of this process, and targeting neutrophil movement during obesity or weight loss improves inflammatory and metabolic outcomes.
Brief Definitive Report
Hannah van Dijk et al.
Plasmodium falciparum circumsporozoite protein harbors conserved human T cell epitopes that may serve as targets for broad strain-transcending immunity. The findings offer guidance for the design of improved malaria vaccines.
Article
Sangya Chatterjee et al.
In this study, we report that microbiota depletion exacerbates acute graft-versus-host disease in the central nervous system, driven by microglial activation and T cell infiltration. Administration of the bacteria-derived metabolite N,N,N-trimethyl-5-aminovaleric acid could rescue both microglial activation and associated neurocognitive deficits.
Article
Heather J. Faust et al.
Type I IFN signaling contributes to arthritis pathogenesis in obesity through activation and expansion of CD8 T cells in visceral adipose tissue and synovium. Deletion of IFNAR1 in T cells reduces arthritis severity in obese mice.
Brief Definitive Report
Aneesha Dasgupta et al.
Cachexia is a devastating cancer comorbidity that impacts numerous cancer outcomes, including therapeutic efficacy, quality of life, and overall survival. This work describes a novel metabolic pathway/target with clinical implications for the treatment of cachectic pancreatic cancer patients.
Journal of Experimental Medicine Cover Image for Volume 222, Issue 7
Current Issue
Volume 222,
Issue 7,
7 July 2025
Reviews & Opinions
Insights
Aman Mangalmurti, John R. Lukens
Yang and colleagues provide an exhaustive study of a novel mouse model of NGLY1 deficiency, a devastating neurological disease, and implicate the cGAS-STING pathway in mediating key disease features which can be rescued using an orally administered STING antagonist.
Insights
Lawrence P. Kane
In this issue of JEM, Malissen and colleagues report that a gain-of-function mutation in CARMIL2, previously identified in patients, is sufficient to replace the contribution of CD28 to NF-κB activation and downstream effects in T cells, including in the setting of an anti-tumor response.
Review | Cancer Focus
Chuangyu Wen et al.
This review highlights how YTHDF proteins regulate tumor responses to radiotherapy by modulating DNA repair and the immune microenvironment and discusses their potential as therapeutic targets to enhance the efficacy of radiotherapy and immunotherapy in cancer treatment.

Most Read

Advertisement

null

Special Collections

Our annual series highlighting articles that were of greatest interest to our readers in 2024.

View collections >

 

or Create an Account

Close Modal
Close Modal